$KPTI
Karyopharm Therapeutics Inc.

2016 Q2 Form 10-Q Financial Statement

#000119312516583808 Filed on May 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $59.00K $0.00 $0.00
YoY Change -60.67% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.960M $5.550M $5.400M
YoY Change -3.25% 2.78% 86.21%
% of Gross Profit
Research & Development $24.58M $21.80M $20.75M
YoY Change -8.99% 5.03% 89.01%
% of Gross Profit
Depreciation & Amortization $180.0K $180.0K $140.0K
YoY Change 20.0% 28.57% 250.0%
% of Gross Profit
Operating Expenses $30.54M $27.35M $26.15M
YoY Change -7.92% 4.59% 88.36%
Operating Profit -$30.48M -$27.35M -$26.15M
YoY Change -7.68% 4.59% 90.71%
Interest Expense $330.0K $290.0K $140.0K
YoY Change 22.22% 107.14% 600.0%
% of Operating Profit
Other Income/Expense, Net $318.0K $290.0K $83.00K
YoY Change 0.0% 249.4% 361.11%
Pretax Income -$30.16M -$27.06M -$26.07M
YoY Change -7.77% 3.79% 90.43%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.16M -$27.06M -$26.07M
YoY Change -7.76% 3.81% 90.35%
Net Earnings / Revenue -51115.25%
Basic Earnings Per Share
Diluted Earnings Per Share -$838.7K -$754.2K -$738.1K
COMMON SHARES
Basic Shares Outstanding 35.96M shares 35.88M shares 35.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.7M $136.4M $246.4M
YoY Change -44.53% -44.64% 70.05%
Cash & Equivalents $37.72M $42.19M $51.45M
Short-Term Investments $85.00M $94.20M $195.0M
Other Short-Term Assets $1.500M $1.700M $2.900M
YoY Change -63.41% -41.38% 7.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $124.2M $138.1M $249.3M
YoY Change -44.86% -44.59% 68.95%
LONG-TERM ASSETS
Property, Plant & Equipment $3.170M $3.343M $3.282M
YoY Change -1.98% 1.86% 919.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $42.90M $50.20M $38.50M
YoY Change 24.71% 30.39%
Other Assets $111.0K $500.0K $500.0K
YoY Change -72.25% 0.0% -49.85%
Total Long-Term Assets $46.70M $53.99M $42.72M
YoY Change 22.75% 26.39% 2385.22%
TOTAL ASSETS
Total Short-Term Assets $124.2M $138.1M $249.3M
Total Long-Term Assets $46.70M $53.99M $42.72M
Total Assets $170.9M $192.1M $292.0M
YoY Change -35.09% -34.21% 95.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.063M $4.109M $6.957M
YoY Change -9.08% -40.94% 112.56%
Accrued Expenses $11.11M $8.652M $7.417M
YoY Change 19.06% 16.65% 378.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.52M $13.22M $14.70M
YoY Change 10.1% -10.07% 193.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.800M $1.900M $1.800M
YoY Change -5.26% 5.56% 958.82%
Total Long-Term Liabilities $1.800M $1.900M $1.800M
YoY Change -5.26% 5.56% 958.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.52M $13.22M $14.70M
Total Long-Term Liabilities $1.800M $1.900M $1.800M
Total Liabilities $17.33M $15.10M $16.52M
YoY Change 8.55% -8.57% 218.51%
SHAREHOLDERS EQUITY
Retained Earnings -$313.7M -$283.6M -$164.4M
YoY Change 59.17% 72.48%
Common Stock $467.2M $460.5M $439.9M
YoY Change 5.08% 4.68% 14663833.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.6M $177.0M $275.5M
YoY Change
Total Liabilities & Shareholders Equity $170.9M $192.1M $292.0M
YoY Change -35.09% -34.21% 95.63%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$30.16M -$27.06M -$26.07M
YoY Change -7.76% 3.81% 90.35%
Depreciation, Depletion And Amortization $180.0K $180.0K $140.0K
YoY Change 20.0% 28.57% 250.0%
Cash From Operating Activities -$20.89M -$23.17M -$20.23M
YoY Change -25.63% 14.53% 91.39%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $39.00K $178.0K
YoY Change -98.31% -78.09% 42.4%
Acquisitions
YoY Change
Other Investing Activities $16.22M $6.790M -$169.9M
YoY Change 1018.62% -104.0% 42375.0%
Cash From Investing Activities $16.22M $6.750M -$170.1M
YoY Change 1786.05% -103.97% 31990.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $90.99M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 240.0K 200.0K 91.16M
YoY Change 1100.0% -99.78% 911500.0%
NET CHANGE
Cash From Operating Activities -20.89M -23.17M -20.23M
Cash From Investing Activities 16.22M 6.750M -170.1M
Cash From Financing Activities 240.0K 200.0K 91.16M
Net Change In Cash -4.430M -16.22M -99.15M
YoY Change -83.72% -83.64% 794.05%
FREE CASH FLOW
Cash From Operating Activities -$20.89M -$23.17M -$20.23M
Capital Expenditures -$10.00K $39.00K $178.0K
Free Cash Flow -$20.88M -$23.21M -$20.41M
YoY Change -24.07% 13.73% 90.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
186000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4109000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8652000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283586000
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
423000
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35960443 shares
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2014Q1 kpti Estimated Future Security Deposit
EstimatedFutureSecurityDeposit
200000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51453000
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35924738 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
14 Securities
CY2016Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35924738 shares
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
460524000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
365000
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1347000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
177036000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
290000
CY2016Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
263000
CY2016Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
198000
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1877000
CY2016Q1 us-gaap Liabilities
Liabilities
15099000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
192135000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1307000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13222000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
94000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
144393000
CY2016Q1 us-gaap Assets
Assets
192135000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
32000
CY2016Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
176012000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3343000
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
485000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
26457000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
138142000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1726000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42188000
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4650000
CY2016Q1 us-gaap Short Term Investments
ShortTermInvestments
94228000
CY2016Q1 us-gaap Long Term Investments
LongTermInvestments
50165000
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
144239000
CY2016Q1 kpti Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
27701 sqft
CY2016Q1 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234 sqft
CY2016Q1 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6650000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150609000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35864765 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
69 Securities
CY2015Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35864765 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
455170000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
301000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2445000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
198365000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
270000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
206000
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
95000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1946000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
26000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3808000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11023000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256527000
CY2015Q4 us-gaap Liabilities
Liabilities
17078000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
215443000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1128000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15132000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
141000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3749000
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
224000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-99156000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
26150000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-170080000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
117851000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
177600000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1967000
CY2015Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
15000000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-282000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
151153000
CY2015Q4 us-gaap Assets
Assets
215443000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
215000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
200325000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3483000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
482000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58358000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4611000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
117275000
CY2015Q4 us-gaap Long Term Investments
LongTermInvestments
33878000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
151342000
CY2015Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
8007000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1 Lease
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20225000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35317181 shares
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
178000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-26067000
CY2015Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-644000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
887000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26150000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-58000
CY2015Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
184902000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
83000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-231000
CY2015Q1 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
486000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26019000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
268000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
91160000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20751000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-11000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1701000
CY2015Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
170000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5399000
CY2016Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
12000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-243000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27349000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
136000
CY2015Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
160000
CY2015Q1 kpti Restricted Shares Common Stock Vested Value
RestrictedSharesCommonStockVestedValue
43000
CY2015Q1 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
90990000
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-23165000
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35878502 shares
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-27059000
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
59003000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
290000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-314000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
343000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26683000
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
33000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
286000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5158000
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
288000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16170000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
27349000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6751000
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
65793000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
196000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21795000
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
48000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2282000
CY2016Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
196000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5554000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
294000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
179000
CY2016Q1 kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000

Files In Submission

Name View Source Status
0001193125-16-583808-index-headers.html Edgar Link pending
0001193125-16-583808-index.html Edgar Link pending
0001193125-16-583808.txt Edgar Link pending
0001193125-16-583808-xbrl.zip Edgar Link pending
d169670d10q.htm Edgar Link pending
d169670dex311.htm Edgar Link pending
d169670dex312.htm Edgar Link pending
d169670dex321.htm Edgar Link pending
d169670dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20160331.xml Edgar Link completed
kpti-20160331.xsd Edgar Link pending
kpti-20160331_cal.xml Edgar Link unprocessable
kpti-20160331_def.xml Edgar Link unprocessable
kpti-20160331_lab.xml Edgar Link unprocessable
kpti-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending